↓ Skip to main content

Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era

Overview of attention for article published in Frontiers in oncology, April 2017

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
7 X users
patent
4 patents

Readers on

mendeley
84 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
Published in
Frontiers in oncology, April 2017
DOI 10.3389/fonc.2017.00083
Pubmed ID
Authors
Abstract

The ability to stratify patients using a set of biomarkers, which predict that toxicity risk would allow for radiotherapy (RT) modulation and serve as a valuable tool for precision medicine and personalized RT. For patients presenting with tumors with a low risk of recurrence, modifying RT schedules to avoid toxicity would be clinically advantageous. Indeed, for the patient at low risk of developing radiation-associated toxicity, use of a hypofractionated protocol could be proposed leading to treatment time reduction and a cost-utility advantage. Conversely, for patients predicted to be at high risk for toxicity, either a more conformal form or a new technique of RT, or a multidisciplinary approach employing surgery could be included in the trial design to avoid or mitigate RT when the potential toxicity risk may be higher than the risk of disease recurrence. In addition, for patients at high risk of recurrence and low risk of toxicity, dose escalation, such as a greater boost dose, or irradiation field extensions could be considered to improve local control without severe toxicities, providing enhanced clinical benefit. In cases of high risk of toxicity, tumor control should be prioritized. In this review, toxicity biomarkers with sufficient evidence for clinical testing are presented. In addition, clinical trial designs and predictive models are described for different clinical situations.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 84 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 13 15%
Researcher 11 13%
Student > Bachelor 9 11%
Professor 4 5%
Student > Master 4 5%
Other 12 14%
Unknown 31 37%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 18 21%
Biochemistry, Genetics and Molecular Biology 13 15%
Agricultural and Biological Sciences 3 4%
Engineering 3 4%
Computer Science 2 2%
Other 10 12%
Unknown 35 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2020.
All research outputs
#4,993,579
of 34,844,563 outputs
Outputs from Frontiers in oncology
#1,719
of 26,812 outputs
Outputs of similar age
#65,533
of 355,393 outputs
Outputs of similar age from Frontiers in oncology
#20
of 87 outputs
Altmetric has tracked 34,844,563 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 26,812 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 355,393 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.